Objective: To assess fesoterodine treatment in elderly women with overactive bladder with and without hypertension. Methods: Data for 2527 elderly women with overactive bladder symptoms, including urgency urinary incontinence, were pooled from 10 double-blind, placebo-controlled fesoterodine studies. Results: A total of 1523 elderly women (60.3%) had a history of hypertension, and 1004 women (39.7%) had no hypertension history. Overactive bladder symptoms, mean bodyweight and mean body mass index at baseline were significantly higher in women with overactive bladder and hypertension versus those without hypertension (P < 0.05). Statistically significant improvements in overactive bladder symptoms at week 12 were observed for fesoterodine treatment versus placebo in women with hypertension and those without (P < 0.05). The diary-dry rate (no urgency urinary incontinence episodes), the proportion with less than eight micturitions/24 h, overactive bladder symptom bother and health-related quality of life were also statistically significantly improved by fesoterodine treatment in both populations. Incidence of treatment-related adverse events with fesoterodine was similar in women with hypertension (39.3%) and without hypertension (44.6%). Dry mouth and constipation were the most common treatmentrelated adverse events with fesoterodine in women with hypertension (26.2% and 5.2%, respectively) and without hypertension (30.5% and 8.0%). Conclusions: A relationship among the severity of overactive bladder symptoms, hypertension and obesity in elderly women is suggested. Fesoterodine provides significantly greater improvements in overactive bladder symptoms and health-related quality of life versus placebo in women with or without hypertension. Hypertension does not appear to affect the efficacy and safety of fesoterodine in elderly women with overactive bladder symptoms, including urgency urinary incontinence.
Introduction
The International Continence Society has defined OAB syndrome as urinary urgency, usually accompanied by frequency and nocturia, with or without UUI, in the absence of urinary tract infection or other obvious pathology. 1, 2 The prevalence of OAB has been estimated as 11.8% in individuals aged ≥18 years in Western countries 3 and 12.4% for individuals aged ≥40 years in Japan. 4 The prevalence of OAB increases with advancing age, as has been shown for countries including Canada, Germany, Italy, Sweden, the UK, France, Spain and Japan. [3] [4] [5] OAB prevalence rates are higher in women than in men, and UUI is consistently more common in women than in men. 6, 7 OAB symptom severity increases progressively with age, including a period of accelerated increase in the sixth decade of life. 8 Based on Medicare claims and Medicare Current Beneficiary Surveys from 2006 to 2011 in the USA, the mean age of elderly patients with OAB (78.5 years) was greater than that of patients without OAB (76.9 years), and patients with OAB were more likely to be aged ≥75 years (65.4%) than those without OAB (53.9%). 9 The rate of elderly (aged ≥65 years) women patients who were prescribed OAB treatment medicines was 84.2%, and the rate of those aged ≥75 years was 63.0% in Japan. 10 Thus, the majority of patients with OAB are elderly in both Western and Eastern countries.
Vascular risk factors (e.g. HT, diabetes, hyperlipidemia and nicotine abuse) might play a role in the development of LUTS. In the USA, elderly patients with OAB had higher rates of comorbid HT, hyperlipidemia and diabetes mellitus than patients without OAB. 9 For example, 57.9% of elderly patients with OAB had comorbid HT versus 43.5% of those without OAB. 9 Women might be more sensitive than men to vascular risk factors. In Japan, the percentage of elderly women with OAB who were co-prescribed an antihypertensive drug was 60.0%. 10 This rate was higher than that in elderly women with or without OAB who were prescribed antihypertensive medicine (37%).
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Although HT is a risk factor for developing OAB, 12 and HT is a common comorbidity in patients with OAB, the characteristics of OAB patients with HT and the efficacy and safety of OAB treatment in this patient population have not been extensively examined. Therefore, we assessed the characteristics of elderly women with OAB and with HT or without HT, and evaluated the efficacy and safety of fesoterodine treatment in these two patient populations.
Methods

Study selection
This pooled analysis included data from 10 identically designed 12-week, randomized, double-blind, placebo-controlled, parallel-group, fesoterodine clinical studies in which participants reported urgency using the USS 13 (Table 1) . [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] The eligible study population consisted of women who were aged ≥65 years. Enrolled participants had to have OAB symptoms for a minimum of 6 months with >0 UUI episodes/24 h at baseline in a bladder diary completed by each participant. Urgency episodes were defined as those with a USS rating of ≥3. Each of the studies had ethics committee approval, and all enrolled patients provided informed consent.
Outcome measures
The outcomes of interest were the baseline characteristics of the elderly women with OAB and with or without HT, including mean (SD) age, weight, BMI, height, UUI episodes/24 h, micturitions/24 h, nocturnal micturitions/24 h, and urgency (USS rating ≥3) episodes/24 h. Concomitant HT was determined based on each participant's medical history in the study case report. The primary end-point of this pooled analysis was the change from baseline to week 12 in the number of UUI episodes/24 h. Secondary efficacy outcomes included the change from baseline to week 12 in micturitions/24 h, nocturnal micturitions/24 h and urgency episodes/24 h; diary-dry rate responders (UUI = 0 for 3 days at end-point); micturition responders (<8 micturitions/24 h at end-point); the change from baseline to week 12 in OAB-q scores for the Symptom Bother and HRQL scales; and the change from baseline in the PPBC. Safety outcomes included the incidence, severity and seriousness of adverse drug reactions. Adverse drug reactions were set as TR-AEs for which a causal relationship with study drugs cannot be ruled out.
Statistical analysis
All analyses were carried out in a post-hoc manner using pooled data. Baseline characteristics were compared between participants with and those without HT using the Student's t-test. The safety analysis set included all patients who took at least one dose of the study drug; TR-AEs were summarized descriptively. Efficacy analyses were based on the full analysis set, which included all patients who took at least one dose of the assigned study drug and had at least one baseline or post-baseline efficacy assessment. For the primary efficacy end-point, an ANCOVA model was used to compare the fesoterodine (8 or 4 mg) and placebo treatment groups in patients with >0 UUI episodes at baseline. The ANCOVA model included terms for treatment and study, with baseline UUI as a covariate. Treatment comparisons were carried out with a two-sided test at a 5% significance level; there was no control for multiplicity. Treatment differences for the change from baseline were estimated for LS means. ANCOVA models were also carried out for the changes from baseline in the secondary bladder diary end-points. Missing data were imputed with the LOCF method. For the PPBC, diary-dry rate responders and micturition responders, the Cochran-Mantel-Haenszel test with modified ridit scoring stratified by study was used to compare the two treatment groups.
Results
Patient characteristics
A total of 2527 elderly patients with OAB were included in the pooled analysis of data from 10 double-blind, placebo-controlled, fesoterodine studies. Of the 2527 elderly women, 91.4% were white, 2.9% were black and 3.7% were Asian. A total of 1523 (60.3%) women had a medical history of HT, and 1004 (39.7%) had no history of HT (Table 2) . At baseline, the mean weight (78.2 kg vs 72.0 kg, P < 0.001) and BMI (30.5 kg/m 2 vs 27.8 kg/m 2 , P < 0.001) of the women with HT were significantly greater than those of the women without HT. In elderly women with HT, the mean number of UUI episodes/24 h (3.63 vs 3.29, P < 0.05), micturitions/24 h (11.95 vs 11.66, P < 0.05), nocturnal micturitions (2.90 vs 2.60, P < 0.001) and urgency episodes/24 h (10.07 vs 9.73, P < 0.05) at baseline were significantly greater than those in elderly women without HT. Baseline demographic and clinical characteristics were similar between the placebo and fesoterodine groups, and between groups of elderly women with and without HT ( Table 3) .
Efficacy of fesoterodine
The mean change from baseline in UUI episodes/24 h at week 12 was significantly greater with fesoterodine versus placebo in both elderly women with HT and those without HT (all P < 0.001; Fig. 1 ). The mean changes from baseline to week 12 in other OAB symptoms assessed in the bladder diary were also significantly greater with fesoterodine versus placebo in both elderly women with HT and those without HT (micturitions/24 h: all P < 0.001; nocturnal micturitions: with HT, P < 0.05; without HT, P < 0.001; urgency episodes/24 h: all P < 0.001). The diary-dry rate (the percentage of participants with no UUI episodes at end-point) and the micturition responder rate (the percentage of participants with <8 micturitions/24 h at end-point) were significantly greater with fesoterodine versus placebo in both elderly women with HT and those without HT (all P < 0.001; Fig. 1 ). PPBC and OAB-q Symptom Bother and total HRQL scores were also significantly improved with fesoterodine over placebo in elderly women with or without HT (all P < 0.001; Table 4 ).
Safety of fesoterodine
The incidence of TR-AEs in fesoterodine-treated elderly women with HT (375/954 [39.3%]) was comparable with that in elderly women without HT (278/623 [44.6%]; Table 5 ). The incidence rates of serious TR-AEs and treatment discontinuations as a result of TR-AEs were low, and similar in fesoterodine-treated patients with HT and those without HT ( Table 5) .
The most frequently reported TR-AEs in fesoterodine-treated elderly women were dry mouth (with HT: 250/954 [26 Table 6 ). In fesoterodine-treated patients, the incidence of urinary retention was 0.5% (5/954 patients) in those with HT and 0.8% (5/623 patients) for those without HT.
Discussion
Premenopausal women are considered to be protected from HT relative to age-matched men, but this protection is lost after the onset of menopause. 25 The majority of female OAB patients are elderly, 10 and HT is hypothesized to be a risk factor for developing OAB. 12 The present pooled analysis showed typical OAB symptoms at baseline were more severe in elderly women with OAB and HT compared with those without HT. In particular, the numbers of nocturia and UUI episodes were greater in elderly women with OAB and HT. The mean number of nocturia episodes was 2.90 times/night in elderly women with OAB and HT, which was 0.30-fold higher than in those without HT. The relationship between HT and nocturia or nocturnal polyuria was supposed. Nocturia of three or more times per night has been associated with a 1.9-fold higher death rate compared with matched cohorts during a follow-up period of 54 months. 26 The mean number of nocturia episodes in elderly women with OAB was almost three times per night. Treatment of night-time micturitions with blood pressure control is necessary to reduce the mortality risk.
The mean number of baseline UUI episodes/24 h was 3.63 in elderly women with OAB and HT, which was 0.34 more UUI episodes/24 h than in those without HT (3.29 UUI episodes/24 h). In an animal study, one possible mechanism explaining the relationship between salt-sensitive HT and urine storage dysfunction could be an increase in adenosine triphosphate and prostaglandin E 2 release from the urothelium through suppression of blood supply to the bladder; 27 hence HT is an aggravating factor for increasing UUI frequency. Nocturia and UUI were more severe in elderly women with OAB that was complicated with HT. Therefore, in elderly women with OAB, comorbid HT negatively affects patient well-being.
The mean weight was 6.2 kg higher in elderly women with OAB with HT than without HT. The mean BMI in elderly women with OAB and HT was >30 kg/m 2 , which is classified as obese according to World Health Organization definitions. 28 The mean BMI in elderly women with OAB and without HT (27.8 kg/m 2 ) was classified as overweight. Increasing evidence has pointed to a relationship between LUTS and the presence of metabolic syndrome, especially BMI, based on recent epidemiological findings. 29, 30 The present study showed a relationship among the severity of OAB symptoms, HT and obesity in elderly women.
Fesoterodine showed statistically significant efficacy versus placebo in reducing the number of UUI episodes per 24 h from baseline to week 12 in both elderly women with HT and those without HT. The reason that UUI was a primary end-point in this pooled analysis is because UUI is considered the main motivator for women to initially visit a hospital for treatment of OAB. The rate of OAB with UUI in women aged ≥40 years in Japan has been reported to be 63.9%. 31 The rate of OAB with UUI in women was higher than the rate in men (41.3%), yet few women sought treatment. For patients with OAB who visited a women's urology outpatient clinic to treat their OAB symptoms, the incidence of OAB with UUI was 90%. 32 Elderly women who are not constrained by time would not visit hospitals when they can control their non-UUI OAB symptoms without changing their daily life. However, experiencing UUI might be a trigger for them to visit a hospital for treatment. Therefore, the efficacy of fesoterodine for improving UUI in elderly women with or without HT is a considerable benefit for elderly women with UUI.
In the present study, significant improvements in nocturnal micturitions were shown with fesoterodine in elderly women with or without HT. Nocturnal micturitions are not only bothersome, but also associated with increased mortality. Furthermore, HT can increase night-time polyuria. Previously, fesoterodine was shown to prolong the amount of undisturbed sleep by approximately one sleep cycle (74-81 min) in Asian patients without nocturnal polyuria (nocturnal polyuria index <33%). 33 This observation might explain the observed clinically meaningful improvements in sleep-related quality of life that were also shown with fesoterodine treatment.
As with the improvements in OAB symptoms, patientreported OAB Symptom Bother and HRQL outcomes, as assessed with the OAB-q, also showed significant improvements with fesoterodine versus placebo in elderly women with OAB and HT or without HT. Thus, fesoterodine showed consistent efficacy in the presence or absence of concomitant HT.
The incidence rates of TR-AEs and serious TR-AEs were similar in elderly women with and without comorbid HT, with dry mouth and constipation being the most common events in both those with HT and those without HT. The incidence of cardiovascular-related TR-AEs was low in both patient populations. Therefore, no new safety risk was found when fesoterodine was given to elderly women with OAB and HT.
Possible limitations of this pooled analysis should be mentioned. Comorbid HT was identified using patients' medical history records because blood pressure measurements were not obtained in all studies. As a result, it is possible that all patients with HT were not captured from the studies. In addition, although each of the studies showed that fesoterodine did not affect blood pressure in the overall population, these analyses were not carried out individually for patients with HT compared with those without it. The relationship between HT and nocturnal polyuria could not be examined because voiding volume was not collected in all studies.
A relationship among obesity, HT and OAB was shown in this pooled analysis. However, a difference in the efficacy of fesoterodine between elderly women with HT and those without HT was not observed.
This pooled analysis was carried out to identify the characteristics of elderly women with OAB who had comorbid HT and to examine whether comorbid HT influences the efficacy and safety of fesoterodine. Differences in baseline characteristics between elderly women with HT or without HT were apparent. Patients with HT had more severe OAB symptoms, and greater weight and BMI values at baseline. Fesoterodine showed statistically significant efficacy in comparison to placebo in reducing UUI episodes and other OAB symptoms in both elderly women with HT and those without HT. Fesoterodine was generally well tolerated in these two patient populations, with no new safety risk detected in patients with comorbid HT. These results suggest that comorbid HT does not affect the efficacy and safety of fesoterodine in elderly women with OAB symptoms, including UUI.
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